- Home
- COGT vs JFR Comparison
COGT vs JFR Comparison
Compare COGT & JFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- JFR
- Stock Information
- Founded
- COGT 2014
- JFR 2004
- Country
- COGT United States
- JFR United States
- Employees
- COGT N/A
- JFR N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- JFR Trusts Except Educational Religious and Charitable
- Sector
- COGT Health Care
- JFR Finance
- Exchange
- COGT Nasdaq
- JFR Nasdaq
- Market Cap
- COGT 1.1B
- JFR 1.1B
- IPO Year
- COGT 2018
- JFR N/A
- Fundamental
- Price
- COGT $12.36
- JFR $8.26
- Analyst Decision
- COGT Strong Buy
- JFR
- Analyst Count
- COGT 11
- JFR 0
- Target Price
- COGT $21.20
- JFR N/A
- AVG Volume (30 Days)
- COGT 1.5M
- JFR 621.7K
- Earning Date
- COGT 11-11-2025
- JFR 01-01-0001
- Dividend Yield
- COGT N/A
- JFR 11.31%
- EPS Growth
- COGT N/A
- JFR N/A
- EPS
- COGT N/A
- JFR N/A
- Revenue
- COGT N/A
- JFR N/A
- Revenue This Year
- COGT N/A
- JFR N/A
- Revenue Next Year
- COGT N/A
- JFR N/A
- P/E Ratio
- COGT N/A
- JFR N/A
- Revenue Growth
- COGT N/A
- JFR N/A
- 52 Week Low
- COGT $3.72
- JFR $7.61
- 52 Week High
- COGT $13.50
- JFR $8.82
- Technical
- Relative Strength Index (RSI)
- COGT 52.66
- JFR 29.85
- Support Level
- COGT $12.28
- JFR $8.38
- Resistance Level
- COGT $13.13
- JFR $8.44
- Average True Range (ATR)
- COGT 0.52
- JFR 0.05
- MACD
- COGT -0.08
- JFR -0.02
- Stochastic Oscillator
- COGT 30.06
- JFR 9.52
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.